Provided By Globe Newswire
Last update: May 16, 2022
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported first quarter 2022 financial results and highlighted recent corporate progress.
NASDAQ:REVBW (4/25/2025, 8:00:01 PM)
0.0108
0 (-28%)
NASDAQ:REVB (4/25/2025, 8:00:01 PM)
2.92
-0.01 (-0.34%)
Find more stocks in the Stock Screener